Latest News by Industry
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 9, 2022--
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November.
Presentation Details:
Event: Jefferies London Healthcare Conference
Location: London, UK
Date/Time: Wednesday, November 16, 2022, at 8:35 AM GMT
Presenter: Noreen Roth Henig, M.D., Chief Medical Officer
Format: Fireside Chat
Event: Evercore ISI 5 th Annual HealthCONx Conference
Location: Boston, MA
Date/Time: Wednesday, November 30, 2022, at 12:10 PM ET
Presenters: John Fowler, Co-Founder, Chief Executive Officer
Format: Fireside Chat
Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221109005819/en/
CONTACT: Investor Contact:
Gitanjali Jain
Vice President, Investor Relations and External Affairs
gjain@kezarbio.comMedia Contact:
Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: Kezar Life Sciences, Inc.
Copyright Business Wire 2022.
PUB: 11/09/2022 04:01 PM/DISC: 11/09/2022 04:02 PM
http://www.businesswire.com/news/home/20221109005819/en